Journal of Hypertension最新文献

{"title":"The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage.","authors":"Martina Hüttl, Matúš Miklovič, Olga Gawryś, Matěj Molnár, Petra Škaroupková, Zdeňka Vaňourková, Soňa Kikerlová, Hana Malínská, Petr Kala, Zuzana Honetschlägerová, Janusz Sadowski, Lenka Hošková, Peter Sandner, Vojtěch Melenovský, Miloš Táborský, Michal Šnorek, Luděk Červenka","doi":"10.1097/HJH.0000000000004009","DOIUrl":"10.1097/HJH.0000000000004009","url":null,"abstract":"<p><strong>Objective: </strong>Despite availability of an array of antihypertensive drugs, malignant hypertension remains a life-threatening condition, and new therapeutic strategies for the treatment of malignant hypertension and malignant hypertension-associated organ damage are needed. The aim of the present study was to assess the effects of nitric oxide (NO)-independent soluble guanylyl cyclase (sGC) stimulator on the course of malignant hypertension. The second aim was to investigate if the treatment with sodium-glucose cotransporter type 2 (SGLT2) inhibitor would augment the expected beneficial actions of the sGC stimulation on the course of malignant hypertension.</p><p><strong>Methods: </strong>As a model of malignant hypertension, Ren-2 transgenic rats (TGR) treated with nonspecific NO synthase inhibitor (Nω-nitro- l -arginine methyl ester, l -NAME) was used. Blood pressure (BP) was monitored by radiotelemetry, and the treatment was started 3 days before administration of l -NAME.</p><p><strong>Results: </strong>The treatment with sGC stimulator BAY 41-8543, alone or combined with SGLT2 inhibitor empagliflozin, abolished malignant hypertension-related mortality in TGR receiving l -NAME. These two treatment regimens also prevented BP increases after l -NAME administration in TGR, and even decreased BP below values observed in control TGR, and prevented cardiac dysfunction and malignant hypertension-related morbidity. The treatment with the SGLT2 inhibitor empagliflozin did not further augment the beneficial actions of sGC stimulator on the course of malignant hypertension-related mortality.</p><p><strong>Conclusion: </strong>The treatment with NO-independent sGC stimulator displayed marked protective actions on the course of malignant hypertension-related mortality and malignant hypertension-related cardiac damage. This suggests that application of sGC stimulator could be a promising therapeutic means for the treatment of malignant hypertension.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1030-1041"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on: \"Long-term cardiovascular repercussions in women with previous pregnancies complicated by severe hypertensive disease\".","authors":"Elizabeth C Cottrell","doi":"10.1097/HJH.0000000000004028","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004028","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"43 6","pages":"949-950"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for chronic hypertension 5 years after a pregnancy complicated by preeclampsia: a systematic review and meta-analysis.","authors":"Lotte W Voskamp, Melek Rousian, Joni J Koerts, Régine P M Steegers-Theunissen, A H Jan Danser, Koen Verdonk","doi":"10.1097/HJH.0000000000003995","DOIUrl":"10.1097/HJH.0000000000003995","url":null,"abstract":"<p><p>Approximately 30% of women with a history of preeclampsia develop chronic hypertension within 10 years of pregnancy. This systematic review summarizes risk factors before, during, and immediately after pregnancy for the development of chronic hypertension 5 years after preeclampsia. Databases were searched with terms 'preeclampsia' and 'postpartum hypertension' or 'cardiovascular disease' up to 30th October 2023. Observational studies reporting chronic hypertension more than 5 years after preeclampsia were included. Quality was assessed using the Newcastle-Ottawa scale. Wherever possible, a meta-analysis was conducted. Twenty-one cohort and five case-control studies, with a median quality score of 8/10, were included, involving 197 793 patients and reporting 32 risk factors. Preeclampsia in a subsequent pregnancy is associated with chronic hypertension [risk ratio (RR) 2.26, 95% confidence interval (CI) 1.59-3.22, n  = 45 626]. Other significant risk factors include early-onset of preeclampsia (<34 weeks gestation), maternal BMI, blood pressure, diabetes, and family history of hypertension.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"939-948"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of pulmonary to systemic vascular resistance ratio in systemic lupus erythematosus patients with pulmonary arterial hypertension.","authors":"Xiaoxiao Guo, Junyan Qian, Jinzhi Lai, Hui Wang, Zhuang Tian, Qian Wang, Jiuliang Zhao, Xiaofeng Zeng, Mengtao Li, Yongtai Liu","doi":"10.1097/HJH.0000000000004010","DOIUrl":"10.1097/HJH.0000000000004010","url":null,"abstract":"<p><strong>Objective: </strong>Pulmonary arterial hypertension (PAH) is a serious complication of systemic lupus erythematosus (SLE) with high mortality. The ratio of pulmonary to systemic vascular resistance (SVR) (Rp : Rs) may increase with disease progression. However, the prognostic value of Rp : Rs in predicting the outcomes of patients with SLE-PAH remains to be elucidated.</p><p><strong>Methods: </strong>Between 1 February 2012, and 30 June 2022, consecutive patients with a diagnosis of SLE-PAH and minimum one follow-up were enrolled prospectively. The end points were all-cause mortality and lung transplantation. The predictive values of baseline clinical characteristics and hemodynamic parameters, including Rp : Rs, were analyzed using Cox proportional hazard analyses. C-statistics were used to compare the predictive ability between the models.</p><p><strong>Results: </strong>A total of 285 patients were included and followed up for a median duration of 3.41 (interquartile range 1.81-5.72), during which 58 (20.4%) patients reached the endpoint. Multivariable Cox regression analysis revealed that in addition to the 6-minute walk distance (6MWD), the Rp : Rs was an independent predictor of the endpoint [hazard ratio 24.72; 95% confidence interval (CI) 5.59-109.29, P  < 0.001] in predicting the endpoint. The concordance index for a model incorporating the Rp : Rs and the 6MWD yielded a value of 0.75 (95% CI 0.68-0.82), which showed better predictive accuracy than the simplified risk stratification strategy. Introducing the Rp : Rs ratio to the 2022 ESC/ERS four-stratum model significantly improved its predictive performance for these patients.</p><p><strong>Conclusion: </strong>The Rp : Rs serves as an independent predictor of adverse prognosis in patients with SLE-PAH and could provide additional value over current risk-assessment tools.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1042-1048"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effects of SARS-CoV-2 infection on blood vessels and blood pressure - LOCHINVAR.","authors":"Stefanie Lip, Tran Q B Tran, Rebecca Hanna, Sarah Nichol, Tomasz J Guzik, Christian Delles, John McClure, Linsay McCallum, Rhian M Touyz, Colin Berry, Sandosh Padmanabhan","doi":"10.1097/HJH.0000000000004013","DOIUrl":"10.1097/HJH.0000000000004013","url":null,"abstract":"<p><strong>Objective: </strong>The COVID-19 pandemic has been linked to endothelial dysfunction and renin-angiotensin-aldosterone system (RAAS) dysregulation, potentially worsening hypertension. Longitudinal studies are needed to establish COVID-19's lasting effects on blood pressure (BP) and endothelial function. Our objective was to determine whether COVID-19 increases future hypertension risk by comparing BP and endothelial function in nonhypertensive COVID-19 survivors with nonhypertensive controls.</p><p><strong>Methods: </strong>This single-centre prospective longitudinal study included participants without hypertension history, with cases being hospital-admitted COVID-19 survivors and controls having negative SARS-CoV-2 antibody tests. Ambulatory blood pressure monitoring, flow-mediated dilatation (FMD), 6-min walk test (6MWT), and quality of life (QoL) assessments were conducted at baseline and 12 months. RAAS phenotyping was performed at baseline. Data analysis used paired t-tests and multivariable regression on full and per-protocol datasets.</p><p><strong>Results: </strong>The full ( n  = 97) and per-protocol ( n  = 66) datasets included 37 and 15 cases respectively. Median ages (IQR: interquartile range) were 49.0 (43.0-53.5) and 50.0 (42-54.0) years. Baseline RAAS parameters were similar. Multivariable adjusted analyses in the per-protocol group showed SARS-CoV-2 positive participants had a 12-month increase in mean systolic BP (4.57 mmHg, [95% CI -0.04 to 9.18], P  = 0.052), diastolic BP (4.46 mmHg [1.01 to 7.90], P  = 0.012), decrease in FMD (-3.15% [-6.33 to 0.04], P  = 0.053) and improvement in 6MWT (145.6 m [49.1 to 242.1], P  = 0.004) compared to controls. QoL assessments indicated continued challenges for recovered COVID-19 individuals at 12 months.</p><p><strong>Conclusions: </strong>Persistent vascular dysfunction and BP increase post-COVID-19 underscore the need for further studies on the long-term risk of hypertension and cardiovascular disease.</p><p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov/study/NCT05087290.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1057-1065"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of incidence of hypertension in France and associated factors: results from the CONSTANCES cohort.","authors":"Lynda Cheddani, Hélène Lelong, Marcel Goldberg, Marie Zins, Jacques Blacher, Sofiane Kab","doi":"10.1097/HJH.0000000000003989","DOIUrl":"10.1097/HJH.0000000000003989","url":null,"abstract":"<p><strong>Introduction: </strong>Estimating hypertension incidence and improving screening in general population could enhance blood pressure control and decrease cardiometabolic risks. Identifying those likely to develop hypertension is essential. Our study focused on predicting onset hypertension and its incidence based on initial characteristics.</p><p><strong>Methods: </strong>We utilized data from the French prospective CONSTANCES cohort, including volunteers assessed twice over 5 years up to 31 December 2019, who were initially free from hypertension. Hypertension was defined as having a SBP at least 140 mmHg or DBP at least 90 mmHg during the second checkup or if antihypertensive medication was prescribed. We calculated annual incidence rates among subgroups and used machine learning models to identify predictors of hypertension. The impact of changes in BMI was analyzed using logistic regression.</p><p><strong>Results: </strong>Of the 11 112 participants (average age 47.5 ± 12 years), 1929 (17.4%) developed hypertension within an average of 5.2 years, with 383 on medication. The incidence rate was 3.4 new cases per 100 person-years, rising with age and consistently higher in men (4.3 vs. 2.8). A blood pressure (BP) threshold of 130 mmHg predicted 70% of new cases. One-point BMI reduction significantly reduced hypertension risk by 16%, regardless of initial BMI and SBP levels.</p><p><strong>Conclusion: </strong>The study reports a notable hypertension incidence of 3.4 new cases per 100 person-years, particularly among those with SBP over 130 mmHg, highlighting the need for regular screening. Early diagnosis and control can mitigate hypertension's adverse effects, emphasizing the crucial role of preventive measures like BMI reduction.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"976-985"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143501844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure variability: a review.","authors":"Spoorthy Kulkarni, Gianfranco Parati, Sripal Bangalore, Grzegorz Bilo, Bum Joon Kim, Kazuomi Kario, Franz Messerli, George Stergiou, Jiguang Wang, William Whiteley, Ian Wilkinson, Peter S Sever","doi":"10.1097/HJH.0000000000003994","DOIUrl":"10.1097/HJH.0000000000003994","url":null,"abstract":"<p><p>Blood pressure variability (BPV) predicts cardiovascular events independent of mean blood pressure. BPV is defined as short-term (24-h), medium or long- term (weeks, months or years). Standard deviation, coefficient of variation and variation independent of the mean have been used to quantify BPV. High BPV is associated with increasing age, diabetes, smoking and vascular disease and is a consequence of premature ageing of the vasculature. Long-term BPV has been incorporated into cardiovascular risk models (QRISK) and elevated BPV confers an increased risk of cardiovascular outcomes even in subjects with controlled blood pressure. Long-acting dihydropyridine calcium channel blockers and thiazide diuretics are the only drugs that reduce BPV and for the former explains their beneficial effects on cardiovascular outcomes. We believe that BPV should be incorporated into blood pressure management guidelines and based on current evidence, long-acting dihydropyridines should be preferred drugs in subjects with elevated BPV.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"929-938"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium channel blockers and mental health: a comprehensive meta-analysis of psychiatric adverse events in double-blind randomized controlled trials.","authors":"Marc-Alexander Fürtig, Yana Kovalenko, Reinhold Kreutz, Thomas G Riemer","doi":"10.1097/HJH.0000000000004011","DOIUrl":"10.1097/HJH.0000000000004011","url":null,"abstract":"<p><strong>Objective: </strong>L-type calcium channel blockers (CCBs) are pivotal in managing cardiovascular disorders, such as hypertension and angina pectoris. Their action on L-type calcium channels, which are not only integral to cardiovascular function but also present in the brain, prompts questions about potential effects on mental health. While previous cohort studies explored this association with mixed results, our study aims to build upon these findings by systematically investigating psychiatric adverse events (PAEs) reported in double-blind randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A systematic search identified double-blind RCTs reporting frequencies of PAEs during CCB therapy across different indications. Separate meta-analyses were conducted for dihydropyridine (DHP) and nondihydropyridine (non-DHP) CCBs against placebo and active controls. This study was registered on INPLASY (INPLASY202480075).</p><p><strong>Results: </strong>In 187 studies, encompassing 28,201 patients exposed to CCBs, several PAEs were reported, with the most common being depression, insomnia, somnolence, and agitation. Meta-analyses revealed no significant difference in PAE occurrence for CCBs vs. placebo, β-blockers, renin-angiotensin system blockers, and thiazide/thiazide-like diuretics (all P  > 0.05). Restricting the analyses to cardiovascular studies, DHP CCBs were linked to lower risks of depression and insomnia compared to placebo [odds ratio (OR) 0.84, confidence interval (CI) 0.70-1.00 and OR 0.38, CI 0.15-0.99, both P  = 0.05); however, these results may be artifacts and should be interpreted with caution.</p><p><strong>Conclusion: </strong>Concerns about negative mental health effects of CCBs appear to be unwarranted and should not deter clinicians from prescribing them when indicated. A detected signal towards positive mental health benefits in cardiovascular patients warrants further investigation.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1049-1056"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation: Erratum.","authors":"","doi":"10.1097/HJH.0000000000004012","DOIUrl":"10.1097/HJH.0000000000004012","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"43 6","pages":"1089"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Day-to-day blood pressure variability in older persons - optimizing measurement.","authors":"Tanya Palsma, Jurgen A H R Claassen, Edo Richard, Rianne A A De Heus","doi":"10.1097/HJH.0000000000003975","DOIUrl":"10.1097/HJH.0000000000003975","url":null,"abstract":"<p><strong>Background: </strong>Higher blood pressure variability (BPV) is associated with adverse clinical outcomes but lack of standardized methodology hampers clinical translation. Day-to-day BPV seems most promising for an older population, especially those with cognitive impairment. This study aimed to determine the optimal number of measurements for obtaining day-to-day BPV in this population.</p><p><strong>Methods: </strong>We included 127 patients attending the geriatric outpatient memory clinic, who measured blood pressure for seven days, morning and evening. Blood pressure measurements of day one were discarded and the coefficient of variation was calculated to assess BPV. Concordance between 7-day BPV (CV 7days ) and a reduced number of measurement days (CV 6days - CV 3days ) was analysed with Bland-Altman plots, intraclass correlation coefficient (ICC), and an a priori determined threshold of a 95% confidence interval (CI) with a lower bound of 0.75.</p><p><strong>Results: </strong>The mean age was 74.6 ± 8.6 years, 49% were female, and had dementia or mild cognitive impairment in 37% and 33% respectively. Reducing the number of measurement days resulted in wider limits of agreement. Concordance decreased when reducing measurement days and reached our predefined threshold with four measurement days (ICC = 0.91, 95% CI = 0.87 - 0.93). BPV derived from five measurement days showed a similar relationship with diagnosis as our reference BPV value obtained with seven days.</p><p><strong>Conclusion: </strong>Our results suggest that systolic home blood pressure should be measured in the morning and evening for at least five consecutive days in duplicate to obtain reliable day-to-day BPV values in older adults with cognitive complaints.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"970-975"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143501835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}